G
Georgette D. Kanmogne
Researcher at University of Nebraska Medical Center
Publications - 39
Citations - 2550
Georgette D. Kanmogne is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Blood–brain barrier & Endothelial stem cell. The author has an hindex of 21, co-authored 38 publications receiving 2283 citations. Previous affiliations of Georgette D. Kanmogne include University of Oklahoma Health Sciences Center & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Blood-brain barrier: structural components and function under physiologic and pathologic conditions
TL;DR: Despite seemingly diverse underlying causes of BBB dysfunction, common intracellular pathways emerge for the regulation of the BBB structural and functional integrity.
Journal ArticleDOI
HIV-1 gp120 compromises blood-brain barrier integrity and enhance monocyte migration across blood-brain barrier: implication for viral neuropathogenesis
Georgette D. Kanmogne,Kathy Schall,Jessica Leibhart,Bryan Knipe,Howard E. Gendelman,Yuri Persidsky +5 more
TL;DR: In this paper, the authors demonstrated that gp120 can cause dysfunction of the blood-brain barrier via PKC pathways and receptor mediated [Ca(2+)](i) release leading to cytoskeletal alterations and increased monocyte migration.
Journal ArticleDOI
HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia.
TL;DR: It is demonstrated that HIV gp120 proteins alter both the functional and molecular properties of the BBB, which could increase trafficking of HIV, infected cells, and toxic humoral factors into the central nervous system and contribute to the pathogenesis of HAD.
Journal ArticleDOI
Maraviroc: a review of its use in HIV infection and beyond
TL;DR: The role of CCR5 in HIV-1 infection, the development of the MVC, its pharmacokinetics, pharmacodynamics, drug–drug interactions, and the implications of these interactions on treatment outcomes are discussed, including viral mutations and drug resistance.
Journal ArticleDOI
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte–macrophage drug delivery
Ari S. Nowacek,Reagan Miller,JoEllyn M McMillan,Georgette D. Kanmogne,Michel Kanmogne,R. Lee Mosley,Zhiya Ma,Sabine Graham,Mahesh Chaubal,Jane Werling,Barrett E. Rabinow,Huanyu Dou,Howard E. Gendelman +12 more
TL;DR: The results support the continued development of macrophage-mediated nanoART carriage for HIV-1 disease and show dose-dependent reduction in progeny virion production and HIV- 1 p24 antigen.